Duodenum

Worldwide Urea Breath Test Industry to 2030 - Players Include Kibion, Avanos Medical, Quest Diagnostics and Paladin Labs - ResearchAndMarkets.com

Retrieved on: 
목요일, 9월 1, 2022
Medical Devices, Health, Instrument, MALT, U.S. Department of Defense Strategy for Operating in Cyberspace, Helicobacter pylori, Human, Human services, Gastric mucosa, Stomach, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ulcer, Death, Gastritis, UBT, Infection, US, SAT, Food, Diagnosis, Esophageal cancer, Biopsy, Region, Lymphoma, American Cancer Society, Office of Inspector General, U.S. Department of Health and Human Services, Duodenum, Time-invariant system, Prevalence, FDA, CAGR, Stomach cancer, Growth, Industry, Bacteria, Marketing, Pharmaceutical industry, Dietary supplement, Fertilizer

The increasing product approvals by the regulatory authorities is expected to drive growth of the global urea breath test market over the forecast period.

Key Points: 
  • The increasing product approvals by the regulatory authorities is expected to drive growth of the global urea breath test market over the forecast period.
  • Pylo Plus UBT System is a 13C urea breath test, designed to detect Helicobacter pylori(H. pylori) infection.
  • There are various test for diagnosing H. pylori such as histopathological examination of the biopsy, immunohistochemical staining, rapid urease test, urea breath test (UBT), and stool antigen test (SAT).
  • However, the preference of urea breath test (UBT) over other tests is increasing, owing to its non-invasive nature.

Insights on the Homatropine Methylbromide Global Market to 2027 - Rising Incidences of Peptic Ulcers are Driving Growth - ResearchAndMarkets.com

Retrieved on: 
목요일, 5월 19, 2022
Health, Pharmaceutical, Incidence, Patient, Government, Stomach, Ulcerative colitis, Ulcer, Antacid, Man, Tablet, Homatropine, CAGR, Homatropine methylbromide, Prevalence, Duodenum, Helicobacter pylori, NCBI, Agriculture, Pharmaceutical industry, Marketing

The global homatropine methylbromide market is anticipated to grow at a considerable CAGR during the forecast period.

Key Points: 
  • The global homatropine methylbromide market is anticipated to grow at a considerable CAGR during the forecast period.
  • The rising incidences of peptic ulcers in the geriatric population are expected to drive the market growth for the global homatropine methylbromide market.
  • Analysis of regional regulations and other government policies impacting the global homatropine methylbromide market.
  • Insights about market determinants that are stimulating the global homatropine methylbromide market.

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

Retrieved on: 
수요일, 5월 11, 2022
Biotechnology, Health, Clinical Trials, Drug development, Duodenum, Volunteering, Brain, University, Mortality, Wound healing, Lists of diseases, IND, Human, Biosplice Therapeutics, Clinical research, Johns Hopkins University, Blood, Type 2 diabetes, Safety, Journal of Clinical Pathology, Food, Doctor of Philosophy, Patient, Insulin, Disease, Type 1, Program, Glucose, Lipodystrophy, Diabetes, Therapy, University of California, San Diego Performance-Based Skills Assessment, Obesity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Industry, Neurodegeneration, Leadership, Adult, Polymer, Osteoarthritis, Vrije Universiteit Amsterdam, Gastrointestinal disease, GI, Weight loss, Amylin, Liver, Technology, Research, Growth, MCP, Medical research, Medicine, Pharmaceutical industry, Medical imaging, T2D

GLY-200 is a proprietary mucin-complexing polymer (MCP) that enhances the natural mucus barrier in the duodenum (the upper small intestine).

Key Points: 
  • GLY-200 is a proprietary mucin-complexing polymer (MCP) that enhances the natural mucus barrier in the duodenum (the upper small intestine).
  • We aspire to replicate the profound effects of metabolic surgery with a safe, accessible, and affordable oral treatment for patients with metabolic conditions.
  • Our clinical candidate, GLY-200, is optimized to treat patients with T2D and potentially reverse the course of disease.
  • GLY-200 was well-tolerated in a completed Phase 1 trial and is being advanced into Phase 2 development for patients with T2D.

NCCN Expands Resources for Treating Rare Cancer Types

Retrieved on: 
수요일, 3월 9, 2022
Consensus, Survival, Lung, Duodenum, Patient, Degenerative disease, Health, Approximation error, Pancreatic duct, Virtual, Consensus decision-making, Peritoneum, Abdomen, Ward E. Pack, EDS, Safety, National Comprehensive Cancer Network, Biliary tract, Colon, National Cancer Institute, Ovarian cancer, Malignancy, Cancer, NCCN, Decision-making, Recurrence, DS, Squamous cell carcinoma, Prostate, Research, BMC, BMC Cancer, Journal of the National Comprehensive Cancer Network, Prognosis, Pancreas, SEER, Policy, USS William M. Wood (DE-287), Caregiver, Medicine, Twitter, Breast, Education, Veni, vidi, vici, Immunotherapy, Amazon (company), Farstad Shipping, Risk management, Dietary supplement, Medical imaging, Medical device, Silviculture, Vaccine, MD

PLYMOUTH MEETING, Pa., March 9, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—today announced the publication of new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ampullary Adenocarcinoma. This evidence- and expert consensus-based resource follows the recent publication of new NCCN Guidelines® for Malignant Peritoneal Mesothelioma, bringing the total number of clinical guidelines to 83.

Key Points: 
  • PLYMOUTH MEETING, Pa., March 9, 2022 /PRNewswire/ --The National Comprehensive Cancer Network (NCCN)an alliance of leading cancer centerstoday announced the publication of new NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ) for Ampullary Adenocarcinoma .
  • NCCN Guidelines are available free-of-charge for non-commercial use at NCCN.org or via the Virtual Library of NCCN Guidelines App .
  • Newly-posted NCCN Guidelines for Patients: Systemic Mastocytosis (a rare mast cell disorder) and updated NCCN Guidelines for Patients: Small Cell Lung Cancer are available as a free download at NCCN.org/patientguidelines or the NCCN Patient Guides for Cancer App , or printed for a nominal fee via Amazon.com.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.

NCCN Expands Resources for Treating Rare Cancer Types

Retrieved on: 
수요일, 3월 9, 2022
Consensus, Survival, Lung, Duodenum, Patient, Degenerative disease, Health, Approximation error, Pancreatic duct, Virtual, Consensus decision-making, Peritoneum, Abdomen, Ward E. Pack, EDS, Safety, National Comprehensive Cancer Network, Biliary tract, Colon, National Cancer Institute, Ovarian cancer, Malignancy, Cancer, NCCN, Decision-making, Recurrence, DS, Squamous cell carcinoma, Prostate, Research, BMC, BMC Cancer, Journal of the National Comprehensive Cancer Network, Prognosis, Pancreas, SEER, Policy, USS William M. Wood (DE-287), Caregiver, Medicine, Twitter, Breast, Education, Veni, vidi, vici, Immunotherapy, Amazon (company), Farstad Shipping, Risk management, Dietary supplement, Medical imaging, Medical device, Silviculture, Vaccine, MD

PLYMOUTH MEETING, Pa., March 9, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—today announced the publication of new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ampullary Adenocarcinoma. This evidence- and expert consensus-based resource follows the recent publication of new NCCN Guidelines® for Malignant Peritoneal Mesothelioma, bringing the total number of clinical guidelines to 83.

Key Points: 
  • PLYMOUTH MEETING, Pa., March 9, 2022 /PRNewswire/ --The National Comprehensive Cancer Network (NCCN)an alliance of leading cancer centerstoday announced the publication of new NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ) for Ampullary Adenocarcinoma .
  • NCCN Guidelines are available free-of-charge for non-commercial use at NCCN.org or via the Virtual Library of NCCN Guidelines App .
  • Newly-posted NCCN Guidelines for Patients: Systemic Mastocytosis (a rare mast cell disorder) and updated NCCN Guidelines for Patients: Small Cell Lung Cancer are available as a free download at NCCN.org/patientguidelines or the NCCN Patient Guides for Cancer App , or printed for a nominal fee via Amazon.com.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.

Fungal Pathway Leads Roswell Park Researchers to New Treatment Target for Pancreatic Cancer

Retrieved on: 
금요일, 2월 4, 2022
Upstate New York, Pancreatic cancer, Patient, Pancreatitis, Cell, Assistant, Neoplasm, Immunology, National Cancer Institute, National, Immunotherapy, Cancer, Disease, Tumor microenvironment, Fungus, NCI, Doctor of Philosophy, Department, Survival, PDAC, Kras, Pancreas, Hope, Duodenum, Mutation, Pharmaceutical industry, Vaccine, Medical imaging, Cancer cell, Roswell Park Comprehensive Cancer Center, Alternaria, Malassezia

BUFFALO, N.Y., Feb. 3, 2022 /PRNewswire-PRWeb/ -- Scientists at Roswell Park Comprehensive Cancer Center have identified a potential new target for the treatment of pancreatic cancer.

Key Points: 
  • BUFFALO, N.Y., Feb. 3, 2022 /PRNewswire-PRWeb/ -- Scientists at Roswell Park Comprehensive Cancer Center have identified a potential new target for the treatment of pancreatic cancer.
  • In a proof-of-concept study, the Roswell Park researchers confirmed that genetic removal of IL-33 decreased tumor burden and prolonged survival.
  • The work was also enabled by several NCI grants (R00CA218891, R01CA262822, R01CA188900, R01CA172105 and P01CA234212) and by donations to Roswell Park.
  • Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York.

Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

Retrieved on: 
수요일, 12월 22, 2021
Annual report, Atopic dermatitis, EOE, Flushing, HPF, Patient, Dysphagia, Private Securities Litigation Reform Act, Ethnologue, Bloating, Abdominal pain, B cell, Securities Act of 1933, Gastrointestinal tract, EG, EOD, Dizziness, Skin, HPFS, Symptoms of COVID-19, Esophagus, Nausea, SEC, Stomach, Asthma, Securities Exchange Act of 1934, Drug Quality and Security Act, Allergy, Headache, TSS, Company, Eosinophil, Safety, Antibody, AK002, Risk, DSQ, Duodenum, Medical imaging, Pharmaceutical industry, Lirentelimab

The safety results of the trial were generally consistent with previously reported lirentelimab studies.

Key Points: 
  • The safety results of the trial were generally consistent with previously reported lirentelimab studies.
  • The randomized, double-blind, placebo-controlled Phase 3 trial of intravenous lirentelimab enrolled 180 patients with EG and/or EoD.
  • The Company plans to initiate a Phase 2/3 study in chronic spontaneous urticaria and a Phase 2 study in asthma in the middle of 2022 and Q4 2022, respectively.
  • These forward-looking statements should not be relied upon as representing Allakos views as of any date subsequent to the date of this press release.

Enteral Collagen Peptide Protein Market - Global Opportunity Analysis and Industry Forecast, 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
목요일, 12월 2, 2021
Medical Devices, Health, Hospitals, Other Health, Fitness & Nutrition, General Health, Patient, Degenerative disease, Conditional sentence, Nursing, Hospital, Population, CAGR, Form, Awareness, Health, Malnutrition, Prevalence, Nutrient, Digestion, Jejunum, Duodenum, Stomach, Clifton Springs Hospital & Clinic, Absorption, Profile, Dysphagia, Growth, Osteoarthritis, Osteoporosis, Joint, Fine chemical, Dietary supplement, Vaccine

The "Enteral Collagen Peptide Protein Market by Form, Age Group and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Enteral Collagen Peptide Protein Market by Form, Age Group and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global enteral collagen peptide protein market was valued at $14,586 thousand in 2020, and is projected to reach $25,811 thousand by 2030, registering a CAGR of 7.2% from 2021-2030.
  • The growth of the global enteral collagen peptide protein market is majorly driven by a rise in the prevalence of chronic illness such osteoarthritis and cardiovascular diseases and increase in application of enteral collagen peptide proteins in the healthcare sector.
  • However, poor demand and lack of awareness of enteral collagen peptide protein products in underdeveloped countries hamper the market growth.

New Assembly Approach Generates Most Complex Stomach Organoids to Date

Retrieved on: 
수요일, 12월 1, 2021
Tissue, Patient, Neuron, BS, Cell, Technology, Achievement, Cincinnati Children's Hospital Medical Center, Tissue engineering, Cell Stem Cell, MD, DO, Doctor of Philosophy, Potency (pharmacology), Microsurgery, Birth, Mouse, Custom, Duodenum, Center, Master of Science, Stomach, Wells, Brunner, Hospital, Transplant, Nerve, Regenerative medicine, PSC, Organoid, Element, Growth, Pharmaceutical industry, 3D printing, Medical imaging, Microscope, Dentistry

And the approach used to produce these multi-layered stomach organoids also can be used to make more-complex versions of other lab-grown organs.

Key Points: 
  • And the approach used to produce these multi-layered stomach organoids also can be used to make more-complex versions of other lab-grown organs.
  • "This advance in tissue engineering is important because we can now assemble complex organ tissues from separately derived components, similar to an assembly line approach," says corresponding author James Wells, PhD.
  • The findings were published Dec. 1, 2021 in Cell Stem Cell by Wells and lead author Alexandra Eicher, PhD.
  • In addition to demonstrating a three-layered approach for developing stomach organoids, the team also applied a similar approach to make a more sophisticated esophageal organoid.

Ohio Physician Becomes the First Doctor in the U.S. to Use Ambu’s Single-Use Duodenoscope in 100 Procedures

Retrieved on: 
목요일, 11월 4, 2021
Oncology, Medical Devices, Health, FDA, Surgery, General Health, Safety, Memorial Hospital of South Bend, Research, Efficiency, Technology, Diagnosis, LinkedIn, Hospital, Cancer, Neoplasm, Twitter, ERCP, Patient, Marketing, FDA, Food, YouTube, Duodenum, Feedback, Inc., Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Physician, Life, Red Dot, Health, Endoscopy, Asia, GI, Multimedia, Pancreas, Ambu, Bile, Solution, Gallstone, Pancreatitis, Medical device, Pharmaceutical industry

Ambu Inc. , the world leader in single-use endoscopy, announced today that an Ohio gastroenterologist has become the first physician in the U.S. to use Ambus new sterile, single-use duodenoscope in 100 endoscopic retrograde cholangiopancreatography (ERCP) procedures.

Key Points: 
  • Ambu Inc. , the world leader in single-use endoscopy, announced today that an Ohio gastroenterologist has become the first physician in the U.S. to use Ambus new sterile, single-use duodenoscope in 100 endoscopic retrograde cholangiopancreatography (ERCP) procedures.
  • View the full release here: https://www.businesswire.com/news/home/20211104005729/en/
    Ambu recognizes Dr. Juan Tejada (left) for performing 100 procedures with its aScope Duodeno.
  • (Photo: Business Wire)
    Dr. Juan Tejada, a gastroenterologist and advanced endoscopist at Memorial Health System in Marietta, Ohio, recently began using Ambus aScope Duodeno , calling it a win for both physicians and patients.
  • Memorial Health System, which operates hospitals in Marietta, Ohio, and health facilities across southeastern Ohio and northwestern West Virginia, also becomes the first hospital system in the U.S. to adopt Ambus aScope Duodeno.